FDA clears thalidomide for leprosy use.
Research is under way to assess its potential value against cancer, autoimmune diseases, and macular degeneration--a leading cause of blindness. Celgene Corp. of Warren, N.J., plans to manufacture the drug, and a team from Boston University will monitor its use on leprosy patients.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Food and Drug Administration|
|Article Type:||Brief Article|
|Date:||Aug 15, 1998|
|Previous Article:||Protein limits bladder cancer spread.|
|Next Article:||Putting the squeeze in superconductors.|